Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Shire To Get Movetis
by Lisa M. Jarvis
August 9, 2010
| A version of this story appeared in
Volume 88, Issue 32
Shire has agreed to pay $430 million for Movetis, a Belgium-based specialty pharmaceuticals firm focused on gastrointestinal products. Shire says Movetis, spun off from Johnson & Johnson in 2006, complements its existing GI portfolio while also expanding its presence outside the U.S. The deal includes Resolor, a chronic-constipation treatment, and a pipeline of GI drug candidates that includes two compounds in Phase II clinical trials and two in preclinical development. Shire expects Resolor’s peak sales to top $400 million per year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter